Research Article

Leptin-LepRb Expressed in Gastric Cancer Patients and Related to Cancer-Related Depression

Yunbao Pan,1 Fuling Zhou,2 Chenyan He,3 Lingyun Hui,4 Tianhe Huang,3 and Yongchang Wei5

1Department of Laboratory Medicine, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 430071, China
2Department of Hematology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 430071, China
3Department of Clinical Oncology, The First Affiliated Hospital, Xi’an Jiaotong University, Xi’an 710061, China
4Department of Clinical Laboratory, The First Affiliated Hospital, Xi’an Jiaotong University, Xi’an 710061, China
5Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 430071, China

Correspondence should be addressed to Yongchang Wei; weiyongchang8@163.com

Received 28 October 2016; Revised 12 January 2017; Accepted 22 January 2017; Published 20 February 2017

Academic Editor: Koichiro Wada

Copyright © 2017 Yunbao Pan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Depression is the most common psychiatric disorder among cancer patients. Studies have not only highlighted that leptin and its receptor (LepRb) are independent poor prognostic factors in gastric cancer (GC) patients but also shown that the leptin-LepRb is necessary for antidepressant-like behaviors. In this study, we examined the serum and tissue leptin-LepRb expression in GC patients. Enzyme-linked immunosorbent assay showed that depressive GC patients had significantly higher serum leptin-LepRb than healthy donors. Leptin-LepRb levels in GC tissues were also significantly higher than in matched paracarcinoma tissues using real-time RT-PCR. Moreover, we observed that both serum and tissue leptin-LepRb were significantly higher in depressive GC patients than those in nondepressive GC patients. Further, the patients with high tumor stage tend to have higher leptin-LepRb mRNA levels than that with low tumor stage. Together, our findings suggest that leptin-LepRb plays an important role in the pathogenesis and depression in GC. Leptin-LepRb therefore could be a potential diagnostic marker and therapeutic target in GC patients with depression.

1. Background

Cancer is a difficult disease, affecting patients both physically and emotionally. Despite medical progress, cancer is often considered synonymous with pain, suffering, and death. However, cancer is not only a certain end but a permanent condition with delayed or late effects of the disease and concurrent psychological disorder [1]. Increased risk for psychiatric morbidity among cancer patients was reported [1, 2]. Recently, depression has received increasing attention in cancer patients. Although depression may be a part of the reaction to diagnosis, depression persists in many patients, creating difficulties in general management and therapy [3]. There is also accumulating evidence indicating that affective and somatic depressive symptoms may occur prior to the establishment of a cancer diagnosis [4]. In addition, depression prolonged hospital stays and decreased survival [5, 6].

Gastric cancer (GC) is the fourth most frequent malignancy worldwide, behind lung cancer, breast cancer, and colorectal cancer. In China, GC is the third cause of death from the cancer [7]. Depression is the most frequent psychiatric issue among cancer patients. Cancer patients are likely to have depressive symptoms after a diagnosis of cancer or during the clinical course of cancer [3]. Studies have demonstrated that overall 21% of gastrointestinal patients suffer from depression [8, 9]. Importantly, patients’ satisfaction with life is associated with depression.

Leptin, a hormone, is primarily produced by adipose tissue and secreted into plasma [10] and could be detected in various tissues [11, 12]. Leptin was initially recognized to control food intake and energy balance [10] and functions via its receptor (LepRb) [13]. Clinical studies demonstrated that elevated serum leptin levels at delivery could eventually serve as a biological marker for the prediction of
depressive symptoms [14], suggesting a regulation of leptin secretion in depressive illness. Moreover, leptin alters long and short antidepressant therapy [15]. Polymorphisms in the leptin gene and decreased leptin are associated with responses to antidepressants [16]. These studies indicated a role of leptin in depressive symptomatology and antidepressant therapy. Signaling pathways, such as Akt and extracellular-regulated kinase (ERK) 1/2, were associated with the therapeutic efficacy of antidepressant efficacy [17, 18]. These pathways are also recruited by leptin via LepRb [19]. Collectively, these findings suggest a critical role of leptin-LepRb in depression and antidepressant therapy.

Leptin-LepRb also regulates cell growth, apoptosis, cell differentiation, migration, and invasion in many carcinomas [20, 21]. Its tumorigenic action is mediated by JAK/STAT, PI3K/PTEN/Akt/mTOR, Raf/MER/ERK pathways [20, 21]. Serum leptin has been detected in various cancers with conflicting results. Decreased leptin levels were demonstrated in gastrointestinal cancer patients [22, 23]. However, increased leptin levels were showed in cachexia gastrointestinal and breast cancer patients [24, 25]. However, there is no report regarding association between leptin and depression in GC patients. The aim of the present study was to investigate the serum and tissue leptin-LepRb levels in GC patients with depression and to examine the relationship between leptin-LepRb and clinical factors in these patients.

2. Materials and Methods

2.1. Patients. All patients were from the First Affiliated Hospitals of Xi’an Jiaotong University (Xi’an, Shaanxi, China) between August 2008 and April 2009. The study group consisted of 56 men and 28 women with GC and the control group consisted of 14 men and 7 women with depression and 17 men and 13 women health donors. Patients who did not receive preoperative chemoradiation treatment were selected for this study. Ethical approval was obtained from the Xi’an Jiaotong University Ethics and Scientific Committee and met international standards for informed consent. The exclusion criteria were uncontrolled infections, cognitive problems, organic or psychotic disorder, a Karnofsky score no more than 70, and antipsychotic or antidepressant treatment. Depression was measured using the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV).

2.2. Enzyme-Linked Immunosorbent Assay (ELISA). The serum leptin and LepRb were detected using ELISA kits (R & D Systems, Minneapolis, MN, USA) according to the manual. Briefly, A total of 50 μL serum were added to ninety-six-well plate coated with antibody and incubation at 37°C overnight. The sections were incubated with the primary antibodies leptin (Abcam, ab16227, Hongkong) and LepRb (Abcam, ab104403, Hongkong) at 1:100 dilution overnight. The sections were incubated with secondary antibody kit (DAKO Corp) and the chromogenic substrate 3,3-diaminobenzidine tetrahydrochloride (DAB). Expression levels of leptin and LepRb were evaluated by online tool, ImmunoRatio (http://153.1.200.58:8080/immunoratio/), which calculates the percentage of positively stained area (labeling index) by using a color deconvolution algorithm for separating the staining components (diaminobenzidine and hematoxylin) and adaptive thresholding for area segmentation [26].

2.3. Real-Time RT-PCR. RNA was extracted from GC tissues and paracarcinoma tissues using RNA extraction kit (QIA-GEN, Venlo, The Netherlands) according to the manual. 1 μg total RNA was exposed to reverse transcription by reverse transcription kit (TaKaRa, Otsu, Shiga, Japan). Real-time PCR were performed using SYBR Green PCR Master Mix (TaKaRa, Otsu, Shiga, Japan). β-Actin gene was served as an internal control. Quantifications of mRNA were performed using the 2^-ΔΔCt method. Primer sequences of leptin were as follows: forward 5’-CTTGACTTGTTGCTATAGGCTGGA-3’; reverse 5’-GTGAGTGGGTTCCTTACCCTTG-3’. Primer sequences of LepRb gene were as follows: forward 5’-TCTTATGCTGGATGTGCCCTTAGAG-3’; reverse 5’-TGAAATTGGTGCCATGCAG-3’.

2.4. Immunohistochemical Analysis. The leptin and LepRb in the formalin-fixed, paraffin-embedded tissue were examined by immunohistochemical analysis. Briefly, the specimens were sectioned (4 μm thick), mounted on Superfrost/Plus slides (Fisher Scientific, Pittsburgh, PA), and deparaffinized in two xylesen and rehydrated through graded alcohols to distilled water. The slides were incubated with the primary antibodies leptin (Abcam, ab16227, Hongkong) and LepRb (Abcam, ab104403, Hongkong) at 1:100 dilution overnight. The sections were incubated with secondary antibody kit (DAKO Corp) and the chromogenic substrate 3,3-diaminobenzidine tetrahydrochloride (DAB). Expression levels of leptin and LepRb were evaluated by online tool, ImmunoRatio (http://153.1.200.58:8080/immunoratio/), which calculates the percentage of positively stained area (labeling index) by using a color deconvolution algorithm for separating the staining components (diaminobenzidine and hematoxylin) and adaptive thresholding for area segmentation [26].

2.5. Statistical Analyses. Results were expressed as mean ± SD. Variance analysis and t-test were used to compare among groups by SPSS software package 17.0. Pearson’s correlation analysis was used to determine the association between depression and tumor stage and association between serum leptin and LepRb levels. P < 0.05 was considered statistically significant.

3. Results

3.1. Patients’ Clinical Characteristics. To analyze the serum leptin and LepRb concentration, we collected blood samples from 30 health donors (median age, 57; range, 29–79 years) and 21 depressive patients (median age, 54; range, 16–69 years) and 27 GC patients (median age, 59; range, 26–79 years). To further analyze the leptin and LepRb mRNA levels in GC, we extracted RNA from 84 GC tissues (median age, 61; range, 26–79 years) and 48 matched paracarcinoma tissues (median age, 59; range, 40–79 years).

3.2. Predictive Value of Leptin and LepRb for Depressive Gastric Cancer. To elicit the relationship between depression and GC, we investigated the depression in 84 GC patients. The percent of patients in T3/T4 tumor stage in depressive cases was higher than that in nondepressive cases (77% versus 53%, P = 0.038, Fisher’s exact test) (Figure 1(a)). Furthermore,
depression was associated with high tumor stage in GC patients ($R = 0.246, P = 0.024$, Pearson’s correlation analysis) (Figure 1(a)).

Expression levels of leptin and LepRb in serum were measured by ELISA. The leptin and LepRb levels were significantly higher in patients who diagnosed GC accompanied with depression (7.9 ng/mL and 5.5 ng/mL, resp.) than in either healthy controls (3.4 ng/mL and 2 ng/mL, resp.) or GC patients (3 ng/mL and 1.9 ng/mL, resp.). However, depression patients had the almost equal serum leptin and LepRb concentration (3.5 ng/mL and 2.3 ng/mL, resp.) with healthy donors (Figures 1(b) and 1(c)).

3.3. Discriminating Potential of Leptin and LepRb in Identifying Gastric Cancer Accompanied with Depression. To further study the leptin and LepRb expression in GC, we examined their mRNA expression in patients’ tissues using real-time RT-PCR. PCR melting curve showed a single peak at ~80°C, 79°C, and 88.5°C from samples genes with leptin, LepRb, and $\beta$-actin, respectively, indicating specific amplification (Figures 2(a) and 2(b)). The leptin and LepRb mRNA levels were significantly increased in patients who diagnosed GC accompanied with depression compared with that of paracarcinoma tissues and GC without depression (depressive GC versus paracarcinoma tissues; 9.3-fold for leptin and 6.5-fold for LepRb, resp.; and depressive GC versus nondepressive GC, 1.4-fold for leptin and 1.4-fold for LepRb, resp.) (Figures 2(c) and 2(d)). Furthermore, we found that leptin in cancer tissue was associated with that in serum ($R = 0.469; P = 0.014$) (Figure 2(e)).

3.4. Leptin and LepRb Protein Expressed in Gastric Cancer. The protein levels of leptin and LepRb in GC tissues were detected by immunohistochemical analysis. The data demonstrated that leptin (Figure 3(a)) and LepRb (Figure 3(b)) protein levels were significantly increased (2.8-fold and 2.3-fold higher) in depressive GC patients ($n = 16$) compared with the nondepressive cancer patients ($n = 16$). These results were consistent with the leptin and LepRb mRNA levels identified in the GC tissues, indicating that leptin and LepRb may be important factors in depressive GC patients.

3.5. Correlation of Leptin and LepRb Expression with Clinic Characteristics. We assessed the mRNA levels of leptin and LepRb with various clinicopathologic variables in 84 GC patients. The patients with high tumor stage (III-IV) had higher leptin-LepRb mRNA levels than that with low tumor stage (I-II). A similar scenario has been obtained with respect to depression; depressive GC patients had higher leptin and LepRb mRNA levels than nondepressive patients. Our results, however, found no significant correlation between leptin-LepRb expression and age, sex, and lymph node metastasis (Table 1).

4. Discussion

As long-term cancer survivors increase, attention has been increasingly paid to cancer-related sequelae and their quality of life, including depression. Clinical depression was considered the most common psychiatric disorder among cancer patients [27]. Two reports using the DSM-III criteria found...
Figure 2: Tissue leptin and LepRb levels in gastric cancer patients. Leptin and LepRb levels in patients’ tissue were detected by real-time RT-PCR. (a, b) PCR melting curve. (c, d) mRNA levels were indicated for leptin and LepRb. (e) Correlation of leptin in serum and cancer tissue at individual patients. * Compared with paracarcinoma tissue, *P<0.05. # Compared with nondepressive gastric cancer, #P<0.05.

Table 1: Expression of leptin and leptin receptor in 84 gastric cancer patients.

| Characteristics          | Leptin expression | P value | LepRb expression | P value |
|--------------------------|-------------------|---------|------------------|---------|
| Age (Y)                  |                   |         |                  |         |
| <65                      | 11.15 ± 2.38      | >0.05   | 11.13 ± 2.63     | >0.05   |
| ≥65                      | 12.27 ± 1.68      |         | 10.33 ± 2.22     |         |
| Gender                   |                   |         |                  |         |
| M                        | 11.56 ± 1.65      | >0.05   | 11.19 ± 2.76     | >0.05   |
| F                        | 12.03 ± 2.04      |         | 12.21 ± 3.21     |         |
| Lymph node metastasis    |                   |         |                  |         |
| Negative                 | 11.62 ± 2.92      | >0.05   | 11.20 ± 2.67     | >0.05   |
| Positive                 | 11.84 ± 2.75      |         | 11.39 ± 2.16     |         |
| Tumor stage              |                   |         |                  |         |
| I-II                     | 9.02 ± 1.65       | <0.05   | 8.37 ± 1.39      | <0.05   |
| III-IV                   | 12.93 ± 2.43      |         | 12.80 ± 2.17     |         |
| Depression               |                   |         |                  |         |
| Positive                 | 17.20 ± 2.71      | <0.05   | 13.00 ± 2.45     | <0.05   |
| Negative                 | 12.40 ± 2.41      |         | 8.45 ± 2.37      |         |
a 42% prevalence of depression [28] and a 33% prevalence in cancer patients [29]. It was reported that more than 20% disease-free breast cancer survivors continued to suffer from depression after completion of therapy. In our study, the DSM-IV scores of almost 41.7% of GC patients indicated depression. Stress appears to affect cancer progression [30]. Stress promotes inflammatory dysregulation and influences immune response in cancer models of depressive behavior [31]. Moreover, stress-induced autonomic response is associated with increased invasive potential [32, 33]. Additionally, stress promotes tumor cells resistance to apoptosis in the proinflammatory tumor microenvironment [34]. Our data indicated that depression was associated with high tumor stage in GC patients, suggesting a potential of depression in accelerating cancer progression.

Initially, leptin was thought to be expressed and secreted only by adipocytes; however, their production in gastric, colorectal, and mammary epithelial tissues has been documented [35–38]. Furthermore, leptin may act as a growth factor, participating in the development of cancer cell lines [39]. Serum leptin levels have been detected in various cancers patients with conflicting results [40–42]; however, the relation between psychiatric status and leptin-LepRb in GC patients has not been reported. In this study, we examined serum and tissue levels of leptin-LepRb in GC patients. In addition, we compared the serum and tissue leptin-LepRb levels between GC patients who suffer from depression and those without depression. We noted that GC patients had slightly lower serum leptin-LepRb levels than healthy donors, however, without statistical difference, and these data are consistent with other reports [25]. However, we observed significantly higher leptin-LepRb levels in GC tissue than in matched paracarcinoma tissue. Moreover, we observed that both serum and tissue leptin-LepRb were significantly higher in depressive GC patients than in nondepressive GC patients. This is the first study to examine the serum and tissue leptin-LepRb levels in GC patients with or without depression.

Although studies demonstrated a critical role of leptin-LepRb in depression and antidepressant therapy, several studies assessed leptin levels in the peripheral blood of people with bipolar disorder, with conflicting results. In mania and depression, some studies indicate that leptin levels are

**Figure 3:** Immunohistochemical analysis of leptin (a) and LepRb (b) expression in nondepressive and depressive gastric cancer tissues. ImmunoRatio was used to evaluate the expression levels. (a) Original image; (b) pseudocolored image; *P < 0.05. GC: gastric cancer.
decreased, some are increased, and some show no difference when compared to healthy controls (reviewed in [43]). Recently, a meta-analysis on 1118 participants demonstrated that serum and plasma leptin levels were not altered in subjects with bipolar disorder when compared to healthy controls in mania, in depression, or in euthymia [43]. Our data are also consistent with this meta-analysis; we did not see difference between depression patients and healthy donors. Serum leptin levels seem to be higher in women than in men [44]. This gender-related difference could be explained by the fact that estrogen stimulates leptin production, whereas testosterone inhibits leptin production [45]. Similarly, our study showed that tissue leptin was slightly higher in women than in men in GC patients without statistical differences. This observation suggested that sex is not a determinant for leptin levels in cancer patients. Our data are also consistent with other studies [44] that age was not associated with leptin in GC patients.

Recently, studies highlighted that leptin-LepRb were independent poor prognostic factors in GC [46]. Leptin-LepRb were correlated with adverse clinicopathological parameters and inversely correlated with survival [46]. Similarly, our study showed that leptin-LepRb levels were higher in T3/T4 stage patients than those T1/T2 patients. As one of explanations for the fact that leptin-LepRb expression group had poor survival, researchers suggested that leptin-LepRb counteracted apoptosis in cancer cells [46]. Further studies are required to clarify the prognostic value of leptin-LepRb in GC.

5. Conclusions

In conclusion, we found that depressive GC patients have increased leptin-LepRb levels compared with nondepressive GC patients. The results from this study indicated that high tumor stage tends to have high serum and tissue leptin-LepRb levels.

Competing Interests

The authors have no conflict of interests to declare.

Authors’ Contributions

Yunbao Pan and Fuling Zhou contributed equally to this work and should be considered as cofirst authors.

Acknowledgments

This work was supported by the fund from the National Natural Science Foundation of China (81673033, 81270597, and 81171288).

References

[1] S. Kuhnt, E. Brähler, H. Faller et al., "Twelve-Month and Lifetime Prevalence of Mental Disorders in Cancer Patients," Psychotherapy and Psychosomatics, vol. 85, no. 5, pp. 289–296, 2016.
[2] S. Swartzman, J. N. Booth, A. Munro, and F. Sani, "Posttraumatic stress disorder after cancer diagnosis in adults: a meta-analysis," Depression and Anxiety, 2016.
[3] M. Hernández Blázquez and J. A. Cruzado, "A longitudinal study on anxiety, depressive and adjustment disorder, suicide ideation and symptoms of emotional distress in patients with cancer undergoing radiotherapy," Journal of Psychosomatic Research, vol. 87, pp. 14–21, 2016.
[4] F. Cosci, G. A. Fava, and N. Sonino, "Mood and anxiety disorders as early manifestations of medical illness: a systematic review," Psychotherapy and Psychosomatics, vol. 84, no. 1, pp. 22–29, 2015.
[5] M. Lloyd-Williams, C. Shiel, F. Taylor, and M. Dennis, "Depression—an independent predictor of early death in patients with advanced cancer," Journal of Affective Disorders, vol. 113, no. 1-2, pp. 127–132, 2009.
[6] G. Pelletier, M. J. Verhoef, N. Khatri, and N. Hagen, "Quality of life in brain tumor patients: the relative contributions of depression, fatigue, emotional distress, and existential issues," Journal of Neuro-Oncology, vol. 57, no. 1, pp. 41–49, 2002.
[7] L. Yang, "Incidence and mortality of gastric cancer in China," World Journal of Gastroenterology, vol. 12, no. 1, pp. 17–20, 2006.
[8] K. Nordin and B. Glimelius, "Psychological reactions in newly diagnosed gastrointestinal cancer patients," Acta Oncologica, vol. 36, no. 8, pp. 803–810, 1997.
[9] K. Nordin, B. Glimelius, L. Påhlman, and P.-U. Sjööden, "Anxiety, depression and worry in gastrointestinal cancer patients attending medical follow-up control visits," Acta Oncologica, vol. 35, no. 4, pp. 411–416, 1996.
[10] A. Ballinger, "Gastric leptin," Gut, vol. 44, no. 2, pp. 153–154, 1999.
[11] A. Babic, Y. Bao, Z. R. Qian et al., "Pancreatic cancer risk associated with prediagnostic plasma levels of leptin and leptin receptor genetic polymorphisms," Cancer Research, vol. 76, no. 24, pp. 7160–7167, 2016.
[12] G. H. Bain, E. Collie-Duguid, G. Murray et al., "Tumour expression of leptin is associated with chemotherapy resistance and therapy-independent prognosis in gastro-oesophageal adenocarcinomas," British Journal of Cancer, vol. 114, no. 12, article e18, 2016.
[13] C. Bjorbaek, S. Uotani, B. Da Silva, and J. S. Flier, "Divergent signaling capacities of the long and short isoforms of the leptin receptor," Journal of Biological Chemistry, vol. 272, no. 51, pp. 32686–32695, 1997.
[14] C. Chen, J. Gao, J. Zhang, L. Jia, T. Yu, and Y. Zheng, "Serum leptin level measured 48 h after delivery is associated with development of postpartum depressive symptoms: a 3-month follow-up study," Archives of Women's Mental Health, vol. 19, no. 6, pp. 1001–1008, 2016.
[15] M. Laimer, K. Kramer-Reinstadler, M. Rauchenzauner et al., "Effect of mirtazapine treatment on body composition and metabolism," Journal of Clinical Psychiatry, vol. 67, no. 3, pp. 421–424, 2006.
[16] S. Kloiber, S. Ripke, M. A. Kohli et al., "Resistance to antidepres- sant treatment is associated with polymorphisms in the leptin gene, decreased leptin mRNA expression, and decreased leptin serum levels," European Neuropsychopharmacology, vol. 23, no. 7, pp. 653–662, 2013.
[17] T. Qin, F. Fang, M. Song, R. Li, Z. Ma, and S. Ma, "Umbelliferone reverses depression-like behavior in chronic unpredictable mild stress-induced rats by attenuating neuronal apoptosis via...
regulating ROCK/Akt pathway,” *Behavioural Brain Research*, vol. 317, pp. 147–156, 2016.

[18] E. Li, H. Deng, B. Wang, W. Fu, Y. You, and S. Tian, “Apelin-13 exerts antidepressant-like and recognition memory improving activities in stressed rats,” *European Neuropsychopharmacology*, vol. 26, no. 3, pp. 420–430, 2016.

[19] O. Kwon, K. W. Kim, and M.-S. Kim, “Leptin signalling pathways in hypothalamic neurons,” *Cellular and Molecular Life Sciences*, vol. 73, no. 7, pp. 1457–1477, 2016.

[20] H. Cao, Y. Huang, L. Wang et al., “Leptin promotes migration and invasion of breast cancer cells by stimulating IL-8 production in M2 macrophages,” *Oncotarget*, 2016.

[21] M. Shen and H. Shi, “Estradiol and estrogen receptor agonists oppose oncogenic actions of leptin in HepG2 cells,” *PLoS ONE*, vol. 11, no. 3, Article ID e0151455, 2016.

[22] A. M. Wallace, A. Kelly, N. Sattar, C. S. McArdle, and D. C. McMillan, “Circulating concentrations of ‘free’ leptin in relation to fat mass and appetite in gastrointestinal cancer patients,” *Nutrition and Cancer*, vol. 44, no. 2, pp. 156–160, 2002.

[23] F. F. Bolukbas, H. Kilic, C. Bolukbas et al., “Serum leptin concentration and advanced gastrointestinal cancers: A Case Controlled Study,” *BMC Cancer*, vol. 4, article 2004.

[24] L. Tessitore, B. Vizio, O. Jenkins et al., “Leptin expression in colorectal and breast cancer patients,” *International Journal of Molecular Medicine*, vol. 5, no. 4, pp. 421–426, 2000.

[25] M. Kerem, Z. Ferahkose, U. T. Yilmaz et al., “Adipokines and ghrelin in gastric cancer cachexia,” *World Journal of Gastroenterology*, vol. 14, no. 23, pp. 3633–3641, 2008.

[26] V. J. Tuominen, S. Ruoostenmäki, A. Viitanen, M. Jumppanen, and J. Isola, “ImmunoRatio: a publicly available web application for quantitative image analysis of estrogen receptor (ER), progesterone receptor (PR), and Ki-67,” *Breast Cancer Research*, vol. 12, no. 4, article R56, 2010.

[27] V. K. Cheruvu and S. C. Oancea, “Current depression as a potential barrier to health care utilization in adult cancer survivors,” *Cancer Epidemiology*, vol. 44, pp. 132–137, 2016.

[28] J. Bukberg, D. Pennman, and J. C. Holland, “Depression in hospitalized cancer patients,” *Psychosomatic Medicine*, vol. 46, no. 3, pp. 199–212, 1984.

[29] M. M. Plumb and J. Holland, “Comparative studies of psychological function in patients with advanced cancer. I. Self-reported depressive symptoms,” *Psychosomatic Medicine*, vol. 39, no. 4, pp. 264–276, 1977.

[30] K. Jin Shin, Y. Jin Lee, Y. Ryoul Yang et al., “Molecular mechanisms underlying psychological stress and cancer,” *Current Pharmaceutical Design*, vol. 22, no. 16, pp. 2389–2402, 2016.

[31] A. Schrepf, S. K. Lutgendorf, and L. M. Pyter, “Pre-treatment effects of peripheral tumors on brain and behavior: neuroinflammatory mechanisms in humans and rodents,” *Brain, Behavior, and Immunity*, vol. 49, pp. 1–17, 2015.

[32] G. N. Armaiz-Pena, S. W. Cole, S. K. Lutgendorf, and A. K. Sood, “Neuroendocrine influences on cancer progression,” *Brain, Behavior, and Immunity*, vol. 30, pp. S9–S25, 2013.

[33] B. Bortolato, T. N. Hyphantis, S. Valpione et al., “Depression in cancer: the many biobehavioral pathways driving tumor progression,” *Cancer Treatment Reviews*, vol. 52, pp. 58–70, 2017.

[34] A. K. Sood, G. N. Armaiz-Pena, J. Halder et al., “Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis,” *Journal of Clinical Investigation*, vol. 120, no. 5, pp. 1515–1523, 2010.

[35] S. J. Hong, K. W. Kwon, S. G. Kim et al., “Variation in expression of gastric leptin according to differentiation and growth pattern in gastric adenocarcinoma,” *Cytokine*, vol. 33, no. 2, pp. 66–71, 2006.

[36] T. Bartha, A. Sayed-Ahmed, and P. Rudas, “Expression of leptin and its receptors in various tissues of ruminants,” *Domestic Animal Endocrinology*, vol. 29, no. 1, pp. 193–202, 2005.

[37] Y. Chilliard, M. Bonnet, C. Delavaud et al., “Leptin in ruminants. Gene expression in adipose tissue and mammary gland, and regulation of plasma concentration,” *Domestic Animal Endocrinology*, vol. 21, no. 4, pp. 271–295, 2001.

[38] N. Aoki, M. Kawamura, and T. Matsuda, “Lactation-dependent down regulation of leptin production in mouse mammary gland,” *Biochimica et Biophysica Acta—General Subjects*, vol. 1427, no. 2, pp. 298–306, 1999.

[39] N. J. Ollberding, Y. Kim, Y. B. Shvetsov et al., “Prediagnostic leptin, adiponectin, C-reactive protein, and the risk of post-menopausal breast cancer,” *Cancer Prevention Research*, vol. 6, no. 3, pp. 188–195, 2013.

[40] T. E. Nakajima, Y. Yamada, T. Hamano et al., “Adipocytokines and squamous cell carcinoma of the esophagus,” *Journal of Cancer Research and Clinical Oncology*, vol. 136, no. 2, pp. 261–266, 2010.

[41] A. G. Farag, N. F. Elnaida, and M. M. El-Dien, “Immunohistochemical expression of leptin in non melanoma skin cancer,” *Journal of Clinical and Diagnostic Research*, vol. 10, no. 8, pp. WC08–WC12, 2016.

[42] G. P. Georgiou, X. Provatoopoulou, E. Kalogera et al., “Serum resistin is inversely related to breast cancer risk in pre-menopausal women,” *Breast*, vol. 29, pp. 163–169, 2016.

[43] B. S. Fernandes, S. Dash, F. Jacka et al., “Leptin in bipolar disorder: a systematic review and meta-analysis,” *European Psychiatry*, vol. 35, pp. 1–7, 2016.

[44] T. W. Stephens, M. Basinski, P. K. Bristow et al., “The role of neuropeptide Y in the antiobesity action of the obese gene product,” *Nature*, vol. 377, no. 6549, pp. 530–532, 1995.

[45] C. Garofalo and E. Surmacz, “Leptin and cancer,” *Journal of Cellular Physiology*, vol. 207, no. 1, pp. 12–22, 2006.

[46] E. Choi, S.-J. Byeon, S. H. Kim et al., “Implication of leptin-signaling proteins and epstein-barr virus in gastric carcinomas,” *PLoS ONE*, vol. 10, no. 7, Article ID e0130839, 2015.